East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Lansoprazole Delayed-Release Orally Disintegrating Tablets, 15 mg and 30 mg. Aurobindo Pharma’s Lansoprazole Delayed-Release Orally Disintegrating Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), PREVACID® SoluTabTM Delayed-Release Orally Disintegrating Tablets manufactured by Takeda Pharms USA, Inc.

Lansoprazole Delayed-Release Orally Disintegrating Tablets are indicated for the following:

• Short-Term Treatment of Active Duodenal Ulcer.
• H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence.
• Maintenance of Healed Duodenal Ulcers.
• Short-Term Treatment of Active Benign Gastric Ulcer.
• Healing of nonsteroidal anti-inflammatory drugs (NSAID)- Associated Gastric Ulcer.
• Risk Reduction of NSAID-Associated Gastric Ulcer.
• Gastroesophageal Reflux Disease (GERD).
• Maintenance of Healing of Erosive Esophagitis (EE).
• Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome (ZES).